Onda 4 Mg/Tab (Ondansetron)

Ondansetron is employed across several clinical pathways that involve nausea and vomiting control.

• Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy.
• Radiation‑induced nausea and vomiting (RINV): Helps control the vomiting that can follow therapeutic radiation.
• Post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea and vomiting after surgical procedures.
• Hyper‑emesis gravidarum (severe pregnancy‑related nausea): Provides symptomatic relief when other treatments are insufficient.

• Ondansetron selectively blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents serotonin‑mediated activation of the vomiting centre, thereby reducing the initiation of nausea and vomiting signals.

Side effects are reported with varying frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Diarrhoea: loose stools.
• Fatigue: general tiredness.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to cardiac arrhythmias.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: agitation, hyperreflexia, tremor when combined with serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes.
• Vision changes: blurred vision or transient visual disturbances.

When using Onda 4 Mg/Tab, consider the following safety measures.

• Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed.
• Concomitant serotonergic drugs: avoid or use with caution due to serotonin syndrome risk.
• Hepatic impairment: dose adjustment may be required in severe liver disease.
• Pregnancy: use only if the potential benefit outweighs risk; discuss with a healthcare professional.
• Breastfeeding: monitor infant for possible effects; decision should be clinician‑guided.
• Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Apomorphine: concurrent use can cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP2D6 substrates (e.g., codeine, tramadol): ondansetron can affect their metabolism.
• Serotonergic agents (e.g., SSRIs, MAO inhibitors): monitor for signs of serotonin syndrome.
• Diuretics causing electrolyte loss: correct electrolytes to reduce cardiac risk.